New York, New York–(Newsfile Corp. – March 31, 2022) – Levi & Korsinsky, LLP notifies investors in Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”) (NASDAQ: FENC) of a class action securities lawsuit.
The lawsuit on behalf of Fennec investors has been commenced in the the United States District Court for the Middle District of North Carolina. Affected investors purchased or otherwise acquired certain Fennec securities between May 28, 2021 and November 26, 2021. Follow the link below to get more information and be contacted by a member of our team:
https://www.zlk.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form?prid=25426&wire=5
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500. There is no cost or obligation to you.
Cannot view this video? Visit:
https://www.youtube.com/watch?v=Oz3SBuPeiA8
Fennec Pharmaceuticals Inc. NEWS – FENC NEWS
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) Fennec had not successfully remediated, and overstated its efforts to remediate, issues with the manufacturing facility of its drug product manufacturer for PEDMARK, a new compound developed to reduce the incidence of hearing loss in children undergoing chemotherapy; (ii) as a result, the Food and Drug Administration likely to approve the Resubmitted Pedmark New Drug Application (“NDA”); (iii) accordingly, the regulatory and commercial prospects of the Resubmitted Pedmark NDA were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
WHAT THIS MEANS TO SHAREHOLDERS: If you suffered a loss in Fennec during the relevant timeframe, you have until April 11, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. Discuss your rights with our legal team without cost or obligation.
PROTECT YOUR FINANCIAL INTERESTS: Complete this brief submission form https://www.zlk.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form?prid=25426&wire=5 or call 212-363-7500 to discuss the case.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/118818